Observational studyMicrobiology spectrum2024

Tocilizumab demonstrates superiority in decreasing C-reactive protein levels in hospitalized COVID-19 patients, compared to standard care treatment alone.

Carolina Calderón-Ochoa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.